Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles

Louis T Curtis1, Min Wu2, John Lowengrub3,4,5

  • 1Department of Bioengineering, University of Louisville, Louisville, Kentucky, United States of America.

Plos One
|December 15, 2015
PubMed

Insights

Smaller nanoparticles (NPs) with high vascular affinity show greater efficacy in targeting tumor vasculature for cancer therapy than larger NPs. Optimal NP size, affinity, and drug release are crucial for effective treatment.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapeutics

Background:

  • Systemic nanoparticle (NP) delivery targets tumor vasculature for cancer therapy, detection, and imaging.
  • Clinical translation is hindered by the complex interactions between NP properties, drug characteristics, and tumor microenvironments.
  • NP vascular affinity, influenced by receptor expression and NP design, is key for endothelial adhesion.

Purpose of the Study:

  • To develop a theoretical framework simulating tumor response to vasculature-bound drug-loaded NPs.
  • To analyze the impact of NP vascular affinity, size, drug loading, and release on NP distribution and accumulation.
  • To elucidate the interplay of these parameters for optimizing NP-based cancer therapies.

Main Methods:

  • Development of a theoretical model to simulate NP behavior in tumor vasculature.
  • In-silico examination of NP distribution, accumulation, and drug release dynamics.
  • Parametric analysis of NP size, vascular affinity, and drug release kinetics.

Main Results:

  • High vascular affinity and smaller NP size (100 nm) promote uniform distribution and efficacy.
  • Larger NPs (1000 nm) exhibit heterogeneous distribution, limiting efficacy despite higher drug loading.
  • Medium vascular affinity with medium/larger NPs offers a balance of distribution and drug release for effective treatment.
  • Increased drug diffusivity benefits heterogeneously distributed NPs but can increase wash-out otherwise.

Conclusions:

  • NP size and vascular affinity are critical determinants of therapeutic efficacy.
  • Optimizing NP design requires balancing size, drug loading, and vascular targeting capabilities.
  • The developed model provides a valuable tool for evaluating and optimizing nanomedicines for vascular-targeted cancer therapy.